A feasibility randomised controlled trial assessing the use of platelet transfusions versus modified dose blood thinners in patients with low platelets and cancer-related blood clots

Not Applicable

• Conditions: Patients with cancer-associated thrombosis and thrombocytopaenia; Haematological Disorders

• Registration Number: ISRCTN77332530
• Lead Sponsor: niversity College London

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-08
• Last Update Posted: 9 September 2024
• Study Completion: 2026-08-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Adult participants (age =18 years) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive/relapsed)
2. Imaging confirmed pulmonary embolism, deep vein thrombosis (proximal or distal, including central venous catheter-related DVT), or unusual site VTE (either symptomatic or incidentally diagnosed) within the last 14 days for which anticoagulation is planned (including VTE in the deep vein system that progressed from a prior superficial vein thrombosis for which anticoagulation is to be started)
3. Platelet count <50 x 10e9/L from cancer therapy or malignancy itself
4. Able to provide written informed consent

Exclusion Criteria

1. Receipt of anticoagulant for index VTE with platelet count <50 x10 9/L for >72 hours
2. Superficial vein thrombosis only
3. Tumour thrombus
4. Life expectancy <1 month (as judged by the treating physicians)
5. Creatinine clearance < 30 ml/min
6. Contraindication to LMWH such as a history of heparin induced thrombocytopaenia
7. Thrombocytopaenia from other causes, such as thrombotic microangiopathy, immune thrombocytopaenia, disseminated intravascular coagulation
8. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies
9. Refusal of blood products
10. Anticoagulation at any dose is deemed unsafe (i.e. recent, active bleeding or inherited bleeding disorders)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary feasibility outcome is the number of participants recruited from all centres per month over 18 months